EURneffy: A Needle-Free Option for Anaphylaxis Treatment in Europe
Availability and Benefits of the New Adrenaline Nasal Spray
Key Highlights of EURneffy Availability in Spain and Europe
- Market Availability: EURneffy is expected to be available in certain European Union Member States, including Spain, by the fourth quarter of 2024.
- Needle-Free Alternative: As the first and only needle-free adrenaline nasal spray approved in the EU, EURneffy offers a significant advantage for patients and caregivers who may have needle phobia or find existing auto-injectors challenging to use.
- Approved Indication: EURneffy is approved for the emergency treatment of allergic reactions (anaphylaxis) caused by various triggers, including insect stings or bites, foods, medicines, and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in adults and children weighing 30 kg or more.
EURneffy, an adrenaline (epinephrine) nasal spray, represents a significant advancement in the emergency treatment of severe allergic reactions, also known as anaphylaxis. Approved by the European Commission on August 22, 2024, EURneffy is the first needle-free option for this life-threatening condition available in the European Union. This offers a new, potentially more accessible, and less intimidating method for administering epinephrine compared to traditional auto-injectors.
Understanding Anaphylaxis and the Need for Timely Treatment
The Critical Role of Adrenaline in Emergency Situations
Anaphylaxis is a severe, potentially fatal allergic reaction that can occur rapidly after exposure to an allergen. Common triggers include certain foods, insect stings, medications, and latex. Symptoms can vary but often involve difficulty breathing, hives, swelling, a drop in blood pressure, and dizziness. Prompt administration of adrenaline is crucial in managing anaphylaxis and preventing serious complications. Adrenaline works by constricting blood vessels, relaxing airway muscles, and reducing swelling, counteracting the effects of the allergic reaction.
Visual Representation of the Impact of Anaphylaxis
Despite the critical need for timely adrenaline administration, studies indicate there is significant underutilization of existing injectable adrenaline products. Factors contributing to this include fear of needles, difficulty in carrying the devices constantly, and the complexity of administration for some individuals, particularly in a high-stress emergency situation. The introduction of a needle-free nasal spray like EURneffy aims to address these barriers and potentially increase the likelihood of patients and caregivers administering adrenaline when needed.
EURneffy's Approval and Anticipated Availability in Spain
Journey to Market and Distribution Plans
The European Commission's approval of EURneffy follows a positive opinion from the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP). The approval was based on extensive studies evaluating the pharmacodynamics and pharmacokinetics of the 2 mg EURneffy dose under various conditions, including self-administration and use in pediatric patients.
Demonstration of Holding the EURneffy Device
ARS Pharmaceuticals, the developer of EURneffy, anticipates making the nasal spray available to patients in certain EU Member States, including Spain, by the fourth quarter of 2024. This rollout is planned to occur through a partnership with a pharmaceutical company that has an established commercial presence in Europe. While specific details regarding the launch in Spain were not explicitly detailed in every source, the inclusion of Spain as an EU member state and the general timeline for availability across "certain European Union Member States" strongly suggests that EURneffy will be accessible in Spain within this timeframe.
How EURneffy Works and Its Advantages
Mechanism of Action and Benefits of Nasal Delivery
EURneffy contains epinephrine, the same active ingredient as injectable adrenaline products. When administered as a nasal spray, epinephrine is absorbed through the nasal passages into the bloodstream, where it can exert its life-saving effects. The 2 mg dose delivered by EURneffy has been studied to ensure appropriate systemic exposure.
Illustrative Use of the Nasal Spray Device
The primary advantage of EURneffy is its needle-free delivery method. This can be particularly beneficial for individuals with needle phobia, which is a significant barrier to carrying and using injectable epinephrine. Additionally, the nasal spray format may be easier for some individuals to administer correctly, especially during the stress of an anaphylactic reaction. EURneffy also offers a smaller form factor and a longer, less temperature-sensitive shelf-life compared to some injectable devices, which could further encourage patients to consistently carry the medication.
Comparison of Delivery Methods
The following table provides a simplified comparison between the delivery methods of traditional injectable epinephrine auto-injectors and EURneffy nasal spray:
| Feature | Injectable Auto-injector | EURneffy Nasal Spray |
|---|---|---|
| Delivery Method | Intramuscular Injection (needle) | Intranasal Spray (needle-free) |
| Ease of Use (Potential) | May require training, can be challenging under stress | Simpler administration, potentially easier for those with needle phobia |
| Portability | Varies by device, can be bulky | Smaller form factor |
| Shelf-life (Temperature Sensitivity) | Can be sensitive to temperature extremes | Longer and less temperature-sensitive shelf-life |
Patient Considerations and Future Access
Who can use EURneffy and what to expect
EURneffy is indicated for use in adults and children weighing 30 kg or more. It is intended for emergency treatment and should be used as directed by a healthcare professional. The instructions for use must be carefully followed, and EURneffy should only be sprayed into a nostril, avoiding the eyes or mouth. In cases where there is no improvement after approximately 10 minutes following the first dose, or if symptoms return or worsen, a second dose of EURneffy should be given in the same nostril, and emergency medical help should be sought immediately.
While EURneffy offers a promising alternative, it's important for patients to discuss with their healthcare provider whether EURneffy is the right treatment option for them. Patients who are comfortable and compliant with their current injectable devices may consider continuing with them until more real-world experience with EURneffy becomes available.
Data Protection and Market Exclusivity
Following its marketing authorization, EURneffy benefits from an eight-year period of data protection in the EU, preventing other applicants from relying on the data submitted for its approval. Additionally, there is a ten-year period of marketing protection, during which generic, hybrid, or biosimilar versions of EURneffy cannot be placed on the market in the EU. This provides a period of exclusivity for ARS Pharmaceuticals and its European partner.
Frequently Asked Questions about EURneffy in Spain
When will EURneffy be available for purchase in Spain?
Based on current information, EURneffy is expected to be available in certain European Union Member States, including Spain, by the fourth quarter of 2024. The exact date may vary depending on the distribution plans of the partnering pharmaceutical company in Spain.
Do I need a prescription to get EURneffy in Spain?
Yes, EURneffy will only be available with a medical prescription in Spain, as it is a prescription medicine for the emergency treatment of anaphylaxis.
Who is EURneffy approved for?
EURneffy is approved for the emergency treatment of allergic reactions (anaphylaxis) in adults and children weighing 30 kg or more.
What types of allergic reactions can EURneffy treat?
EURneffy is used for the emergency treatment of anaphylaxis caused by insect stings or bites, foods, medicines and other allergens, as well as idiopathic (unknown cause) anaphylaxis or anaphylaxis caused by exercise.
Is EURneffy a replacement for seeking emergency medical attention?
No, EURneffy is for emergency treatment and should be used as a first-line intervention while simultaneously seeking emergency medical help. After administering EURneffy, it is crucial to seek immediate medical attention.
References
Last updated April 20, 2025